DYADIC INTERNATIONAL INC (DYAI) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, DYADIC INTERNATIONAL INC's filing signal continuing negative.

Dyadic International, Inc., operating as Dyadic Applied BioSolutions, is a global biotechnology company focused on developing and commercializing precision-engineered, animal-free recombinant proteins and enzymes. Leveraging its proprietary C1 and DapibusTM microbial expression platforms, the company targets applications in life sciences, food and nutrition, and bio-industrial markets. Dyadic's commercialization strategy involves direct sales, distribution partnerships, manufacturing collaborations, and technology licensing, aiming to generate near-term revenue while advancing its platforms for broader applications. The company has achieved commercialization of products like AlbuFreeTM DX and recombinant DNase I, with ongoing development in areas such as cell culture media, dairy enzymes, and industrial enzymes.

Revenue is primarily driven by research collaborations, grants, and sublicensing agreements, which can include upfront payments, milestone payments, development funding, product supply revenues, and revenue-sharing arrangements.